Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Add filters

Year range
EuropePMC; 2021.
Preprint in English | EuropePMC | ID: ppcovidwho-314052


Background: Seroprevalence surveys are useful in estimating past infections and provide an appraisal of the cumulative number of infections in a population. We designed a population-based survey in Kashmir to estimate the seroprevalence of SARS-CoV-2 specific IgG antibodies in the general population aged 18 years and above. Methods: The survey was conducted among 110 villages and urban wards across ten districts in Kashmir from 17 Oct 2020 to 04 Nov 2020. Serum samples were tested for the presence of SARS-CoV-2 specific IgG antibodies using the Abbott SARS-CoV-2 IgG assay. Seroprevalence estimates were adjusted for the sampling design and assay characteristics. Findings: Out of 6397 eligible individuals enumerated, 6315 (98.7%) agreed to participate. The final analysis was done on 6230 participants. Seroprevalence adjusted for the sampling design and assay characteristics was 36.7% (95% CI 34.3%-39.4%). Seroprevalence was higher among the older population. Only one-half of symptomatic individuals reported having been tested. One out of every ten seropositive individuals reported a history of COVID-19 like symptoms. We estimated an infection fatality rate of 342 deaths per million infections. Interpretation: During the first seven months of the COVID-19 epidemic in Kashmir valley, approximately 37% of individuals were infected. There is still a significant pool of susceptible people in Kashmir. The number of infections will continue to rise unless infection prevention measures are practiced by the population. Funding: National Health Mission Jammu &Kashmir Declaration of Interests: We declare no competing interests, financial or otherwise. Ethics Approval Statement: The study was approved by the Institutional Ethics Committee of Government Medical College Srinagar.

Clin Case Rep ; 9(3): 1397-1401, 2021 Mar.
Article in English | MEDLINE | ID: covidwho-1025073


Our work highlights patients at risk of prolonged viral shedding in COVID-19 and its implications for isolation strategies and explores possible solution by PCR-CT value testing (cycle threshold value). We also review the impact of HIV on COVID-19.

Respir Med Case Rep ; 31: 101265, 2020.
Article in English | MEDLINE | ID: covidwho-885430


BACKGROUND: Coronavirus disease 2019 (Covid-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It mainly affects the lungs and common symptoms are fever, cough and shortness of breath. Pneumothorax has been noted to complicate Covid-19 cases requiring hospital admission, however the exact incidence and risk factors are still unknown. DISCUSSION: We present a series of 3 cases of primary spontaneous pneumothorax with Covid-19 pneumonia. All cases in our series did not require positive pressure ventilation and none had any pre-existing lung disease. All were never smokers and had favourable outcomes despite having severe Covid-19 with a pneumothorax during the course of the disease. In our literature review we discuss several plausible mechanisms and risk factors resulting in a pneumothorax with Covid-19. CONCLUSION: Our cases are a reminder that an acute deterioration with hypoxia in a Covid-19 patient could indicate a pneumothorax. Pneumothorax is one of the reported complications in Covid-19 and clinician vigilance is required during assessment of patients, as both share the common symptom of breathlessness and therefore can mimic each other.